Traws Pharma
TRAW
16 hedge funds and large institutions have $5.97M invested in Traws Pharma in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
23% more funds holding
Funds holding: 13 → 16 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.24% less ownership
Funds ownership: 54.12% → 49.88% (-4.2%)
70% less capital inflows, than outflows
Capital inflows: $489K | Capital outflows: $1.61M
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$216K |
| 2 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$68.2K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$64.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$63.1K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$59.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$447K |
| 2 |
Armistice Capital
New York
|
-$373K |
| 3 |
EcoR1 Capital
San Francisco,
California
|
-$348K |
| 4 |
Kepos Capital
New York
|
-$326K |
| 5 |
Panagora Asset Management
Boston,
Massachusetts
|
-$49K |
TRAW Hedge Fund Activity: Q4 2018 in Review
16 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2018, worth a combined $5.97M — down 74% from $22.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TRAW positions and 3 closed out — a net gain of 3 holders — while 0 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $216K. The largest seller was Vanguard Group, cutting an estimated $447K.
- 16 institutional investors held Traws Pharma (TRAW) as of Q4 2018, up from 13 in Q3 2018.
- Funds reported $5.97M of Traws Pharma stock for Q4 2018, down 74% quarter-over-quarter.
- 6 funds opened new Traws Pharma positions in Q4 2018 and 3 closed out, a net change of +3 holders.
- The largest Traws Pharma buyer in Q4 2018 was Sabby Management, an estimated $216K added.
- The largest Traws Pharma seller in Q4 2018 was Vanguard Group, an estimated $447K sold.
Based on aggregated 13F filings for Q4 2018.